Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead

10th February 2025 Uncategorised 0

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types.

More: Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
Source: fierce